Pricing

Carisma Therapeutics Inc (CARM)

followers ·
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Thomas R. Cannell
Employees:
20
3675 MARKET STREET, SUITE 200, PHILADELPHIA, PA, 19104
2674916422
Stock Split History
DateRatio
2023-03-08 1:20
Carisma Therapeutics Inc. a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) Its lead product candidates include Vicineum, which is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer. The company was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available